Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF

BACKGROUND: Patients with heart failure with reduced ejection fraction (HFrEF) in Asia exhibit many differences from those in other parts of the world. OBJECTIVES: This study sought to investigate the efficacy and safety of dapagliflozin, compared with placebo, in HFrEF patients in Asia, compared wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Docherty, Kieran F., Anand, Inder S., Chiang, Chern-En, Chopra, Vijay K., Desai, Akshay S., Kitakaze, Masafumi, Verma, Subodh, Vinh, Pham N., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Langkilde, Anna Maria, Jhund, Pardeep S., McMurray, John J.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627879/
https://www.ncbi.nlm.nih.gov/pubmed/36339117
http://dx.doi.org/10.1016/j.jacasi.2022.02.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627879/
https://www.ncbi.nlm.nih.gov/pubmed/36339117
http://dx.doi.org/10.1016/j.jacasi.2022.02.004

Ejemplares similares